PL374829A1 - Kompozycje do hamowania białkowej kinazy C alfa do leczenia cukrzycy i chorób sercowo-naczyniowych - Google Patents

Kompozycje do hamowania białkowej kinazy C alfa do leczenia cukrzycy i chorób sercowo-naczyniowych

Info

Publication number
PL374829A1
PL374829A1 PL03374829A PL37482903A PL374829A1 PL 374829 A1 PL374829 A1 PL 374829A1 PL 03374829 A PL03374829 A PL 03374829A PL 37482903 A PL37482903 A PL 37482903A PL 374829 A1 PL374829 A1 PL 374829A1
Authority
PL
Poland
Prior art keywords
treatment
protein kinase
diabetes mellitus
activity
cardiovascular diseases
Prior art date
Application number
PL03374829A
Other languages
English (en)
Inventor
Jan Menne
Hermann Haller
Original Assignee
Phenos Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phenos Gmbh filed Critical Phenos Gmbh
Publication of PL374829A1 publication Critical patent/PL374829A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PL03374829A 2002-09-24 2003-09-23 Kompozycje do hamowania białkowej kinazy C alfa do leczenia cukrzycy i chorób sercowo-naczyniowych PL374829A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10244453A DE10244453A1 (de) 2002-09-24 2002-09-24 Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten

Publications (1)

Publication Number Publication Date
PL374829A1 true PL374829A1 (pl) 2005-10-31

Family

ID=31969524

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03374829A PL374829A1 (pl) 2002-09-24 2003-09-23 Kompozycje do hamowania białkowej kinazy C alfa do leczenia cukrzycy i chorób sercowo-naczyniowych

Country Status (19)

Country Link
US (2) US20050250719A1 (pl)
EP (2) EP1545560B1 (pl)
JP (1) JP2006503841A (pl)
KR (1) KR20050059180A (pl)
CN (1) CN1684694A (pl)
AT (1) ATE475422T1 (pl)
AU (1) AU2003280288B2 (pl)
CA (1) CA2499818A1 (pl)
DE (3) DE10244453A1 (pl)
DK (1) DK1545560T3 (pl)
EA (1) EA007926B1 (pl)
ES (1) ES2356286T3 (pl)
IS (1) IS7777A (pl)
MX (1) MXPA05002930A (pl)
NO (1) NO20051242L (pl)
NZ (1) NZ538857A (pl)
PL (1) PL374829A1 (pl)
UA (1) UA88257C2 (pl)
WO (1) WO2004028516A2 (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20031714A1 (it) 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.
CA2538999A1 (en) * 2003-09-19 2005-03-31 Children's Hospital Medical Center Regulation of cardiac contractility and heart failure propensity
EP1687410A4 (en) * 2003-10-07 2008-04-09 Isis Pharmaceuticals Inc ANTISENSE OLIGONUCLEOTIDES OPTIMIZED TO TARGET THE KIDNEY
US9144594B2 (en) * 2005-11-08 2015-09-29 University Of Miami Cathepsin L mediated diseases and associated methods and products
JP2009518439A (ja) * 2005-12-09 2009-05-07 メタプロテオミクス，エルエルシー ホップ及びアカシア産物によるプロテインキナーゼ調節
US20080181877A1 (en) * 2006-03-22 2008-07-31 Leangene Ab, C/O Cit Ekonomiservice Ab Method For Monitoring the Effect of Compounds on Foxc2 Expression
US9636317B2 (en) 2007-01-31 2017-05-02 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters
US9974764B2 (en) 2007-01-31 2018-05-22 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters in the treatment of neoplasms
US10369222B2 (en) 2012-01-18 2019-08-06 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters for the treatment of stroke
US11696908B2 (en) 2007-01-31 2023-07-11 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters
RU2472511C2 (ru) 2007-01-31 2013-01-20 Биосаксесс Биотех Кампани Композиции и способы применения форболовых эфиров
US11564901B2 (en) 2007-01-31 2023-01-31 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters
US9533938B2 (en) 2007-01-31 2017-01-03 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters for the treatment of stroke
EP1982722A1 (en) * 2007-04-16 2008-10-22 Gentium S.p.A. Use of oligotide for the treatment of renal diseases
AU2010300531A1 (en) 2009-09-30 2012-05-24 President And Fellows Of Harvard College Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
CN107007617A (zh) 2010-11-12 2017-08-04 真蒂奥姆责任有限公司 去纤维蛋白多核苷酸用于预防和/或治疗移植物抗宿主病(gvhd)
US9550722B2 (en) 2012-01-18 2017-01-24 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbal esters for the treatment of stroke
WO2013110006A2 (en) * 2012-01-18 2013-07-25 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters
US10099996B2 (en) 2012-01-18 2018-10-16 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters in the treatment of neoplasms
WO2013182905A2 (en) * 2012-06-05 2013-12-12 Jonas Axelsson Mechanism, diagnostic, and treatments for complications of renal failure
AU2012383169B2 (en) 2012-06-22 2017-12-21 Gentium S.R.L. Euglobulin-based method for determining the biological activity of defibrotide
TWI750481B (zh) * 2013-01-18 2021-12-21 美商華鴻新藥股份有限公司 用於中風治療之巴豆酯組成物及使用方法
TWI687217B (zh) * 2014-01-10 2020-03-11 華鴻新藥股份有限公司 用於中風治療之巴豆酯組成物及使用方法
CA2937447A1 (en) * 2014-01-29 2015-08-06 Vaxine Pty Ltd New target for diabetes treatment and prevention.
KR102320082B1 (ko) * 2014-04-14 2021-10-29 아비나스 오퍼레이션스, 인코포레이티드 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
US10752699B2 (en) 2015-06-29 2020-08-25 Regents Of The University Of Minnesota Anti-APOBEC3 antibodies and methods of making and using
EP3421485A1 (en) 2017-06-30 2019-01-02 Université de Strasbourg Peptides for treatment and prevention of hyperglycaemia
CN111386240A (zh) * 2017-09-29 2020-07-07 安全工程有限责任公司 具有直流电源的提升机系统
RU2765117C2 (ru) * 2019-09-24 2022-01-25 Федеральное государственное автономное образовательное учреждение высшего образования "Уральский федеральный университет имени первого Президента России Б.Н. Ельцина" Применение натриевой соли диэтилового эфира 4-оксо-1,4-дигидропиразоло[5,1-с]-1,2,4-триазин-3,8-дикарбоновой кислоты, моногидрата в качестве средства лечения и профилактики поздних осложнений сахарного диабета
WO2022092884A1 (ko) * 2020-10-29 2022-05-05 가톨릭관동대학교산학협력단 13-ｏ-아세틸포볼을 포함하는 골질환 및 혈관석회화증 예방 또는 치료용 약학적 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3914764A1 (de) * 1989-05-05 1990-11-08 Goedecke Ag Maleinimid-derivate und deren verwendung als arzneimittel
DE3924538A1 (de) * 1989-07-25 1991-01-31 Goedecke Ag Indolocarbazol und dessen verwendung
HUT64837A (en) * 1990-10-01 1994-03-28 Brigham & Womens Hospital Preparatives of beta-carotine and those of vitamine e having ulceration inhibiting effect
EP0507938A4 (en) * 1990-11-02 1993-03-10 Sphinx Pharmaceuticals Corporation Bis-(hydroxyalkylamino)-anthraquinone inhibitors of protein kinase c
AU1783092A (en) * 1991-04-08 1992-11-02 United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Inhibitors of protein kinase c function
DK0817627T3 (da) 1993-12-23 2005-06-06 Lilly Co Eli Inhibitorer af proteinkinase C
US5491242A (en) 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors
US5481003A (en) 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
DE69600784T2 (de) * 1995-11-20 1999-04-08 Lilly Co Eli Proteinkinase-C-Inhibitor
CA2252701C (en) * 1996-05-01 2003-10-28 Mississippi State University Halo-substituted protein kinase c inhibitors
US6063814A (en) * 1997-04-14 2000-05-16 Chang; Richard L. Phorbol esters as anti-neoplastic and white blood cell elevating agents
DE19740384A1 (de) * 1997-09-08 1999-03-11 Max Delbrueck Centrum Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN
CA2538999A1 (en) * 2003-09-19 2005-03-31 Children's Hospital Medical Center Regulation of cardiac contractility and heart failure propensity

Also Published As

Publication number Publication date
KR20050059180A (ko) 2005-06-17
NZ538857A (en) 2010-10-29
DK1545560T3 (da) 2010-11-22
CA2499818A1 (en) 2004-04-08
EA200500529A1 (ru) 2005-08-25
NO20051242L (no) 2005-06-01
MXPA05002930A (es) 2005-09-30
AU2003280288B2 (en) 2008-08-28
DE10244453A1 (de) 2004-04-01
JP2006503841A (ja) 2006-02-02
WO2004028516A3 (de) 2004-11-11
ATE475422T1 (de) 2010-08-15
DE10393825D2 (de) 2005-08-11
CN1684694A (zh) 2005-10-19
AU2003280288A1 (en) 2004-04-19
IS7777A (is) 2005-03-30
US20090191194A1 (en) 2009-07-30
ES2356286T3 (es) 2011-04-06
EA007926B1 (ru) 2007-02-27
EP1545560A2 (de) 2005-06-29
US20050250719A1 (en) 2005-11-10
EP2338498A1 (de) 2011-06-29
WO2004028516A2 (de) 2004-04-08
EP1545560B1 (de) 2010-07-28
UA88257C2 (ru) 2009-10-12
DE50312935D1 (de) 2010-09-09

Similar Documents

Publication Publication Date Title
PL374829A1 (pl) Kompozycje do hamowania białkowej kinazy C alfa do leczenia cukrzycy i chorób sercowo-naczyniowych
RS51449B (sr) Kombinacija aktivatora peroksizom proliferator-aktiviranog receptora (ppar) i inhibitora apsorpcije sterola i lečenje vaskularnih indikacija
NO20053837L (no) Farmasoytisk blanding for profylakse eller behandling av kardiovaskulaere-, kardiopulmonaere-, pulmonaere- eller nyresykdommer.
AU2002350191A8 (en) Substituted heteroarylalkanoic acids and their use as aldose reductase inhibitors
NO20044534L (no) Substituerte fenylacetamider og deres anvendelse som glukokinaseaktivatorer
EP1400529A4 (en) GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL AND INTERMEDIARY USE THEREOF
BR0210167A (pt) Composto, composição farmacêutica, métodos para modular um receptor ativado com proliferador de peroxissoma, para tratar ou prevenir uma doença ou condição e para abaixar a glicose no sangue, e, uso de um composto
NO20042161L (no) Inhibitorer av 11-beta-hydroksysteroid dehydrogenase type 1
NO20054743L (no) Guanidinderivater og anvendelse derav som neuropeptid FF reseptor antagonister
DK1176956T3 (da) Carboxylsyrederivater, som inhiberer bindingen af integriner til deres receptorer
FR2768621B1 (fr) Utilisation d'un extrait d'au moins un vegetal de la famille des rosacees
MY147642A (en) Novel anthranilamide pyridinureas as vascular endothelial growth factor (vegf) receptor kinase inhibitors
WO2002066450A3 (en) Anthrone derivatives and their use as ink inhibitors
WO2004024093A3 (en) Device and method for treating restenosis
PE20040291A1 (es) COMBINACION QUE COMPRENDE UN INHIBIDOR DE HMG-CoA-REDUCTASA Y UN POTENCIADOR DE LA SECRECION DE INSULINA Y/O UN SENSIBILIZANTE DE INSULINA
AP2001002377A0 (en) Substituted phenoxyacetic acids.
MXPA05001712A (es) Bifenilcarboxamidas sustituidas con n-aril piperidina como inhibidores de la secrecion de apolipoproteina b.
PL376213A1 (pl) Kompozycja farmaceutyczna do zapobiegania lub leczenia chorób sercowo-naczyniowych, sercowo-płucnych, płucnych lub nerek
ATE397599T1 (de) Als modulatoren der chemokinrezeptoraktivität geeignete piperidinderivate
CA2341638A1 (en) Use of a midkine inhibitor
WO2000048447A3 (en) Composition for treatment of external secretion disorders except hypolacrimation
NO20043286L (no) Piperidinderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
HK1097406A1 (en) Selective peroxisome proliferator activated receptor modulators
WO2005058243A3 (en) Methods for treating cancer using vascular endothelial cell growth inhibitor vegi-192a
NZ535199A (en) Use of an inhibitor or antagonist against tissue factor

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)